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  (-)-Depudecin (1) (Figure 1), isolated from the culture broths of the fungus Alternaria brassicicola,1 
and later, from the weed pathogen Nimbya scirpicola,2 has been identified as a selective inhibitor of histone 
deacetylases (HDAC) with an IC50 in the low M range.3 In contrast to representative HDAC inhibitors, 
depudecin represents a unique inhibitor of these enzymes by virtue of its molecular structure, featuring the 
presence of two oxirane rings separated by a trans double bond. Originally discovered as part of a biological 
screening directed towards the identification of antitumour agents with detransforming activity,4 depudecin 
was identified as a bioactive metabolite capable of reverting the transformed morphology of tumor cells. 
This biological activity elicited a great biomedical and biological interest by virtue of its potential as an 
antitumor agent as well as for further understanding the biological roles of HDACs. Depudecin induced not 
only morphological changes but also cell cycle arrest and cellular differentiation,5 and also exhibited 
remarkable anti-angiogenesis activity.6 Prompted by its striking biological properties and enticing structure, 
we decided to initiate a research program directed towards the synthesis of natural depudecin. Our synthetic 
plan has recently culminated with linear and convergent total syntheses.7  
 
Now, we have synthesized an array of depudecin analogues, including truncated and stereoisomeric 
analogues. With the aim to explore their biological activity, we have performed preliminary biological 
evaluations, which consisted of the measurement of the antitumor properties of the generated analogues 
against a panel of various tumor cell lines, including the human promyelocytic leukemia (HL60), human 
breast adenocarcinoma (MDA-MB-231), human fibrosarcoma (HT1080) and gioblastoma (U87MG), as well 
as a primary culture of nontransformed bovine aorta endothelial (BAEC) cells, which may indicate a putative 
antiangiogenic effect.8 In this communication we report the synthesis and biological activity of an array of 
depudecin analogues which led us to a structure-activity relationship (SAR) study of this intriguing natural 
product. 
 
 
 
Figure 1. Structure of (-)-Depudecin and Proposed Analogues for SAR study. 
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